Medical Specialties · attribution context sourced from stored price moves, stored event labels, and peer-relative residuals inside the JPJY constituent company universe.
Review priority 90 · Source rank 0 · Volume 3.3x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.67% · Sector -0.21% · Industry +0.92% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +15.10%Review priority 89 · Source rank 0 · Volume 3.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.02% · Sector +0.78% · Industry +0.71% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +13.70%Review priority 86 · Source rank 0 · Volume 4.9x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +1.20% · Sector -1.09% · Industry -0.49% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -11.65%Review priority 83 · Source rank 0 · Volume 5.7x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro +0.17% · Sector -0.24% · Industry -0.01% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -10.51%Review priority 82 · Source rank 0 · Volume 3.8x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -1.85% · Sector +2.26% · Industry +0.46% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +10.28%Review priority 80 · Source rank 54 · Volume 2.0x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -5.77% · Sector +7.85% · Industry +0.71% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -12.73%Review priority 80 · Source rank 0 · Volume 3.2x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.92% · Sector +1.28% · Industry +0.50% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual +10.37%Review priority 80 · Source rank 60 · Volume 3.6x
Source gap missing_direct_company_catalyst · Next action research_company_specific_news
Decomposition: Macro -0.08% · Sector -0.20% · Industry -3.01% · Peer Specific +0.00% · Company Catalyst +0.00% · Unexplained Residual -9.59%| Date | Label | Move | Residual after context | Scope | Confidence |
|---|---|---|---|---|---|
| Mar 13, 2020 | Broad market moved -5.77% with this stock | -9.93% | -12.73% | Macro | 58% |
| Feb 16, 2026 | Closest peers moved -3.28% with this stock | -12.87% | -9.59% | Peer | 58% |
| Apr 7, 2025 | Broad market moved -8.37% with this stock | -11.04% | -10.05% | Macro | 58% |
| Apr 8, 2025 | Broad market moved +5.85% with this stock | +8.78% | +10.18% | Macro | 58% |
| Apr 10, 2025 | Broad market moved +8.26% with this stock | +8.82% | +10.42% | Macro | 58% |
| May 13, 2022 | Closest peers moved +3.35% with this stock | +8.49% | +5.13% | Peer | 58% |
| Mar 25, 2020 | Broad market moved +8.49% with this stock | +9.88% | +6.37% | Macro | 58% |
| May 13, 2026 | Olympus Corp - To Retire Treasury Shares Worth 2.69% Of Outstanding Stock On April 30, 2027 | +19.83% | +0.58% | Direct | 71% |
| May 13, 2026 | Olympus: FY2027 guidance projects accelerated growth, margin expansion, and robust capital returns | +19.83% | +0.58% | Direct | 82% |
| May 13, 2026 | Olympus: To Buy Back Up to Y60B of Own Shares by End-March 2027 | +19.83% | +0.58% | Direct | 76% |